General Metabolics (GMet) is excited to announce the opening of its new U.S.-based laboratory in Boston, Massachusetts. After previously operating out of the ETH in Zurich, Switzerland, metabolomics studies from our U.S. and international clients will now be handled exclusively by GMet’s Boston laboratory. “Boston is a global center for biomedical research and is an outstanding location for our company,” said Edward Driggers, Ph.D., GMet’s Founder and Managing Director, “We are surrounded by multiple world-class universities and hospitals, as well as hundreds of biopharma companies. We are eager to make our technology platform a regular part of the R&D workflow for researchers here in Boston, Cambridge, and beyond.”
The new facility will continue to provide access to the same cutting-edge metabolomics capabilities that were available in Zurich, including GMet’s exclusive high-throughput non-targeted metabolite profiling platform to support studies from 50 to 50,000 samples with rapid turnaround. In addition, GMet’s new facility will provide targeted metabolomics methods to support end-to-end metabolism research. “We are very excited to see GMet launching operations in the United States. Zurich was a terrific starting point for the company, and we are delighted to see GMet expanding capabilities worldwide,” said Nicola Zamboni, Ph.D., a co-Founder of GMet and Professor at ETH.
Please contact us if you would like to hear more about our capabilities.
